New late-breaking data to be presented today by the Australian and New Zealand Urogenital and Prostate (ANZUP) Clinical ...
UCL trial of 6,000 prostate cancer patients found the Decipher genetic test indicates which tumours are going to spread amid ...
A new deep learning architecture called TexTNet integrates local binary pattern texture features into a Swin Transformer's ...
ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use ...
A prostate cancer diagnosis can leave men weighing several consequential decisions, from active surveillance and regular monitoring to surgery and radiation therapy.
Early-stage studies presented at ESMO reported promising activity for several experimental treatments for advanced prostate cancer. Johnson & Johnson’s oral JNJ-6143 produced substantial PSA declines ...
A meta-analysis of 22 phase III randomized trials found that ARPI-containing prostate cancer treatments were associated with ...
5d
Mount Sinai and Brooke Shields Urge Families to Have “The Talk” About Prostate Cancer Screening
The PSA launches as Mount Sinai researchers begin EXPAND-PC, a five-year, $4.2 million project funded by the National Institutes of Health (NIH) to develop and evaluate a community-based approach to ...
Protein phosphatase 2A plays a central role in controlling many cell signaling pathways, which are frequently disrupted ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results